MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$60,000K
(-53.85%↓ Y/Y)
Proceeds from issuance of
common stock under...
$65K
(-65.61%↓ Y/Y)
Net cash provided by
investing activities
$30,024K
(-57.62%↓ Y/Y)
Net cash (used in)
provided by financing...
$65K
(-65.61%↓ Y/Y)
Canceled cashflow
$29,976K
Net (decrease)
increase in cash, cash...
-$7,147K
(-293.27%↓ Y/Y)
Canceled cashflow
$30,089K
Share-based compensation
$3,215K
(-74.83%↓ Y/Y)
Accounts payable and
accrued liabilities
$2,259K
(115.47%↑ Y/Y)
Depreciation and
amortization
$153K
(-63.74%↓ Y/Y)
Purchases of marketable
securities
$29,976K
(-49.80%↓ Y/Y)
Net cash used in
operating activities
-$37,236K
(44.71%↑ Y/Y)
Canceled cashflow
$5,627K
Net loss
-$42,286K
Prepaid expenses and
other assets
$367K
(112.18%↑ Y/Y)
Operating lease
right-of-use assets and...
-$161K
(-866.67%↓ Y/Y)
Accretion of discounts on
marketable securities, net
$49K
(-97.30%↓ Y/Y)
Back
Back
Cash Flow
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)
source: myfinsight.com